Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study

L. Falchero; Florian Guisier; Marie Darrason; Arnaud Boyer; C. Dayen; Sophie Cousin; P. Merle; R. Lamy; Anne Madroszyk; Josiane Otto; Pascale Tomasini; Sandra Assoun; Anthony Canellas; Radj Gervais; J. Hureaux; J. Le Treut; O. Leleu; Charles Naltet; Marie Tiercin; Sylvie Van Hulst; Pascale Missy; Franck Morin; Virginie Westeel; Nicolas Girard

doi:10.1016/j.lungcan.2023.107379

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

IFCT-1905 CLINATEZO shows reproductibility, in real-life,ofIMpower-133survival outcomes, possibly attributed to selection of patients fit for this regimen, adoption of pragmatic approaches,including concurrent radiotherapy and treatment beyond progression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Falchero et al. (2023) studied this question.

synapsesocial.com/papers/69d7d52f2f3446b9d5d17ebf https://doi.org/10.1016/j.lungcan.2023.107379

View Full Paper

Ask AI

Bookmark

Share

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study

Ask about this paper

Abstract

Discussion

Cite This Study

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading